Literature DB >> 26130439

Human telomerase inhibitors from microbial source.

Kalarikkal Gopikrishnan Kiran1, Muthusamy Palaniswamy, Jayaraman Angayarkanni.   

Abstract

Telomerase enzyme inhibitors have gained attention of scientific field due to the specificity of action of telomerase based therapies. Some telomerase have good combinatorial action with certain DNA damaging drugs. Natural compounds isolated from microbes provide a new scope of screening and large scale production of telomerase inhibitors. This review emphasizes the biochemistry and mode of action of different types of telomerase inhibitors isolated from microbial sources. Also elaborates on classification of telomerase inhibitors based on their mode of action in cancer cells.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26130439     DOI： 10.1007/s11274-015-1893-3

Source DB:  PubMed          Journal:  World J Microbiol Biotechnol        ISSN： 0959-3993            Impact factor:   3.312


  88 in total

Review 1.  Natural products as sources of new drugs over the period 1981-2002.

Authors:  David J Newman; Gordon M Cragg; Kenneth M Snader
Journal:  J Nat Prod       Date:  2003-07       Impact factor: 4.050

2.  Inhibition of telomerase by G-quartet DNA structures.

Authors:  A M Zahler; J R Williamson; T R Cech; D M Prescott
Journal:  Nature       Date:  1991-04-25       Impact factor: 49.962

3.  TRAP-LIG, a modified telomere repeat amplification protocol assay to quantitate telomerase inhibition by small molecules.

Authors:  Julie Reed; Mekala Gunaratnam; Monica Beltran; Anthony P Reszka; Ramon Vilar; Stephen Neidle
Journal:  Anal Biochem       Date:  2008-05-17       Impact factor: 3.365

4.  Macrocyclic hexaoxazoles as sequence- and mode-selective G-quadruplex binders.

Authors:  Masayuki Tera; Hiromichi Ishizuka; Motoki Takagi; Masami Suganuma; Kazuo Shin-ya; Kazuo Nagasawa
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

5.  Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991.

Authors:  Hiroyuki Seimiya; Tomoko Oh-hara; Tsuneji Suzuki; Imad Naasani; Toshiyuki Shimazaki; Katsutoshi Tsuchiya; Takashi Tsuruo
Journal:  Mol Cancer Ther       Date:  2002-07       Impact factor: 6.261

6.  Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb.

Authors:  Takeshi Miyazaki; Yang Pan; Kaushal Joshi; Deepti Purohit; Bin Hu; Habibe Demir; Sarmistha Mazumder; Sachiko Okabe; Takao Yamori; Mariano Viapiano; Kazuo Shin-ya; Hiroyuki Seimiya; Ichiro Nakano
Journal:  Clin Cancer Res       Date:  2012-01-09       Impact factor: 12.531

7.  Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction.

Authors:  Lynne W Elmore; Catherine W Rehder; Xu Di; Patricia A McChesney; Colleen K Jackson-Cook; David A Gewirtz; Shawn E Holt
Journal:  J Biol Chem       Date:  2002-07-05       Impact factor: 5.157

8.  Specific interactions of distamycin with G-quadruplex DNA.

Authors:  Melanie J Cocco; L A Hanakahi; Michael D Huber; Nancy Maizels
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

Review 9.  Telomerase and cancer therapeutics.

Authors:  Calvin B Harley
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

10.  The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments.

Authors:  Katia Cortese; Mark T Howes; Richard Lundmark; Erica Tagliatti; Paola Bagnato; Annalisa Petrelli; Maria Bono; Harvey T McMahon; Robert G Parton; Carlo Tacchetti
Journal:  Mol Biol Cell       Date:  2012-11-14       Impact factor: 4.138
View more
  2 in total

Review 1.  Telomerase as a Cancer Target. Development of New Molecules.

Authors:  D L Mengual Gomez; R G Armando; C S Cerrudo; P D Ghiringhelli; D E Gomez
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

Review 2.  Therapeutic Targeting of Telomerase.

Authors:  Kathrin Jäger; Michael Walter
Journal:  Genes (Basel)       Date:  2016-07-21       Impact factor: 4.096
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.